Affiliation of Author(s):[1]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Dept Pharm,Personalized Drug Therapy Key Lab Sichu, Chengdu 610072, Peoples R China;[2]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu 610072, Peoples R China;[3]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Lab Med, Chengdu 610072, Peoples R China;[4]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Hlth Management Ctr, Chengdu 610072, Peoples R China;[5]Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Chinese Acad Med Sci 2019RU026, Res Unit Blindness Prevent, Chengdu 610072, Peoples R China;[6]Jianyang Peoples Hosp Sichuan Prov, Dept Pharm, Jianyang 641400, Peoples R China
Journal:ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES
Key Words:Small interfering RNA; Tumor microenvironment; siRNA delivery; Cancer therapy; Co-delivery
Abstract:How to effectively transform the pro-oncogenic tumor microenvironments (TME) surrounding a tumor into an anti-tumoral never fails to attract people to study. Small interfering RNA (siRNA) is considered one of the most noteworthy research directions that can regulate gene expression following a process known as RNA interference (RNAi). The research about siRNA delivery targeting tumor cells and TME has been on the rise in recent years. Using siRNA drugs to silence critical proteins in TME was one of the most efficient solutions. However, the manufacture of a siRNA delivery system faces three major obstacles, i.e., appropriate cargo protection, accurately targeted delivery, and site-specific cargo release. In the following review, we summarized the pharmacological actions of siRNA drugs in remolding TME. In addition, the delivery strategies of siRNA drugs and combination therapy with siRNA drugs to remodel TME are thoroughly discussed. In the meanwhile, the most recent advancements in the development of all clinically investigated and commercialized siRNA delivery technologies are also presented. Ultimately, we propose that nanoparticle drug delivery siRNA may be the future research focus of oncogene therapy. This summary offers a thorough analysis and roadmap for general readers working in the field.(c) 2023 Published by Elsevier B.V. on behalf of Shenyang Pharmaceutical University. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
Document Type:Review
Volume:18
Issue:5
ISSN No.:1818-0876
Translation or Not:no